Learn More
PURPOSE Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non-small-cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or without(More)
  • K Kelly, L Lovato, +6 authors David R. Gandara
  • Clinical cancer research : an official journal of…
  • 2001
PURPOSE This study was designed to determine the efficacy and toxicity of cisplatin, etoposide, and paclitaxel (PET) in patients with extensive-stage small cell lung cancer (ES-SCLC). EXPERIMENTAL(More)
  • 1